Videos

Matthew Galsky, MD, discusses the future of bladder cancer research and the impact of new treatments such as immune checkpoint inhibitors and antibody-drug conjugates.

Alexandra S. Zimmer, MD, discusses treatment options for patients with HER2-positive breast cancer who have developed brain metastasis.

Karen Reckamp, MD, and Jyoti Patel, MD, outline their treatment approaches for patients with ALK+ NSCLC who progress on frontline TKIs.

Jyoti Patel, MD, and Karen Reckamp, MD, share insights on factors to consider when selecting the appropriate therapy for patients with ALK+ advanced NSCLC.

Nino Balanchivadze, MD, FACP, discusses the methods used in the retrospective analysis of KEYNOTE-189 study, to determine the differences in the rate of renal toxicity based on race in patients with non-squamous non-small cell lung cancer.

Giuseppe Giaccone, MD, PhD, discusses alterations in the MET gene that can be oncogenic drivers in patients with non–small cell lung cancer.

Bhavana Pothuri, MD, discusses the importance of determining biomarkers of patients with endometrial cancer to decide on treatment options.

Recommendations to increase the uptake of CAR T-cell therapies into clinical practice when managing patients with relapsed/refractory diffuse large B-cell lymphoma.

Variables that are likely to impact the use of loncastuximab vs a combination approach with tafasitamab and lenalidomide to treat relapsed/refractory diffuse large B-cell lymphoma.

Evanthia Roussos Torres, MD, PhD, discusses the follow-up research related to the phase 1 study of entinostat administered in combination with nivolumab and ipilimumab for the treatment of locally advanced, metastatic, unresectable, or HER2-negative breast cancer.

Shaakir Hasan, DO, discusses for potential reasons for continuing racial disparities in bladder cancer despite years of evidence of the issue.

Daniel P. Petrylak, MD, discusses the impact of the approval of apalutamide in the metastatic castration-sensitive prostate cancer setting.

Elisabetta Abruzzese, MD of S. Eugenio Hospital, discusses the management of pregnancy in patient with chronic myeloid leukemia.

Anthony El-Khoueiry, MD, provides a brief review of sequencing therapy for patients with cholangiocarcinoma in the modern treatment landscape.

Focused discussion on the adverse events that may occur when managing cholangiocarcinoma with targeted therapies.

A comprehensive review of chemotherapy and targeted agents available to treat cholangiocarcinoma throughout various lines of therapy.

Expert insight on the current role of biomarker testing and targeted therapy in cholangiocarcinoma management.

Anthony El-Khoueiry, MD, reviews cholangiocarcinoma subtypes and outlines strategies in identification and diagnosis.

An overview of the LOTIS-1 clinical trial and the rationale for the accelerated approval of loncastuximab for relapsed/refractory diffuse large B-cell lymphoma.

Recommendations for managing patients with diffuse large B-cell lymphoma on tafasitamab.

John C. Byrd, MD, discusses the early results and adverse events observed in the ELEVATE-RR trial in patients with chronic lymphocytic leukemia.

Mark A. Socinski, MD, discusses the patient population of the trials targeting MET exon 14 skipping mutations in non–small cell lung cancer.

Thomas Powles, MD, MBBS, MRCP, discusses the safety profile of enfortumab vedotin in urothelial cancers as observed in the phase 3 urothelial cancerstrial.

Next steps investigating novel-based therapies for newly diagnosed metastatic renal cell carcinoma.

Advice to oncology nurses who manage patients with metastatic renal cell carcinoma receiving novel-based therapies, including lenvatinib and pembrolizumab.

An overview of data demonstrated by other investigational studies of lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma.

Implications for treating patients with metastatic renal cell carcinoma with frontline lenvatinib plus pembrolizumab, based on the regimen’s performance in the CLEAR study compared with other options.

Reactions to efficacy and safety data demonstrated by the CLEAR study of lenvatinib plus pembrolizumab as first-line treatment for metastatic renal cell carcinoma.

The rationale for investigating the combinations of lenvatinib plus pembrolizumab and lenvatinib plus everolimus as frontline therapy for metastatic renal cell carcinoma.

An overview of current novel-based approaches for metastatic renal cell carcinoma and current treatment gaps.